Advertisement
GILD vs MEDX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Buy and MEDX is a Buy.
GILD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GILD turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 40 of 54 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on GILD as a result. In 59 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 215 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 167 of 276 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for GILD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 17 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 44%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 24 of 63 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 38%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.495) is normal, around the industry mean (-1.421). GILD's P/E Ratio (-63.943) is considerably lower than the industry average of (21.700). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.038) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
MEDX in upward trend: 10-day moving average crossed above 50-day moving average on October 23, 2026
The 10-day moving average for MEDX crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MEDX as a result. In 52 of 61 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for MEDX just turned positive on October 12, 2026. Looking at past instances where MEDX's MACD turned positive, the stock continued to rise in 26 of 32 cases over the following month. The odds of a continued upward trend are 81%.
MEDX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDX advanced for three days, in 181 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 162 of 189 cases where MEDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for MEDX moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 54 cases where MEDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
MEDX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
GILD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 8 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| GILD | MEDX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 44% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 38% | 2 days ago 67% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 83% |
| Advances ODDS (%) | 2 days ago 64% | 3 days ago 82% |
| Declines ODDS (%) | 6 days ago 47% | 9 days ago 73% |
| BollingerBands ODDS (%) | 2 days ago 43% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GILD’s FA Score shows that 3 FA rating(s) are green while .
- GILD’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GILD’s TA Score shows that 4 TA indicator(s) are bullish.
- GILD’s TA Score: 4 bullish, 4 bearish.
Price Growth
GILD (@Pharmaceuticals: Major) experienced а +2.03% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.33%. For the same industry, the average monthly price growth was +2.53%, and the average quarterly price growth was +7.15%.
Reported Earning Dates
GILD is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-1.33% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
MEDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDX has been loosely correlated with OGN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDX jumps, then OGN could also see price increases.
| Ticker / NAME | Correlation To MEDX | 1D Price Change % | ||
|---|---|---|---|---|
| MEDX | 100% | -0.30% | ||
| OGN - MEDX | 43% Loosely correlated | +0.29% | ||
| SNY - MEDX | 40% Loosely correlated | +0.23% | ||
| MRK - MEDX | 36% Loosely correlated | -0.48% | ||
| GILD - MEDX | 34% Loosely correlated | +0.92% | ||
| BIIB - MEDX | 32% Poorly correlated | -0.64% | ||
More | ||||